Learning biostatistics for clinical trials: the statistics you need first

What clinical-trial biostatistics actually is

Biostatistics is the branch of statistics that applies to biology and medicine; clinical-trial biostatistics is the sub-branch that owns the design and analysis of randomised experiments in humans. It answers questions the field can't reason through by intuition: how big does the trial need to be? Which participants count in the primary analysis if some drop out? Is a small effect real, or noise? Is the observed benefit large enough to matter, or just measurable?

Every drug approval, every device authorisation, every clinical guideline that says "this intervention works" sits on top of a statistical analysis someone had to defend to a regulator. The design decisions are typically frozen in a Statistical Analysis Plan (SAP) before the first patient is enrolled — because once the results are in, the choice of test is no longer neutral.

A staged learning path

The mistake most self-learners make is jumping straight to adaptive designs, Bayesian trials, or MMRM without owning the layer underneath. Learn the three tiers in order.

Layer 1 — statistical foundations

The bedrock you can't skip:

• Descriptive statistics — Table 1 of every trial paper. Means with SDs for continuous, counts with percentages for categorical, medians with IQRs when distributions are skewed.
• Inference basics — what a p-value actually means, when to use t-test or ANOVA, when to reach for a non-parametric alternative.
• Confidence intervals — the mature way to report a treatment effect, and the anchor of estimation-based reasoning. Modern reporting guidelines (CONSORT) want the CI beside every point estimate.
• Regression — the workhorse for baseline-adjusted analyses. Linear regression for continuous endpoints; logistic for binary; Cox for time-to-event. ANCOVA (regression with a treatment factor plus a baseline covariate) is almost always more powerful than a plain t-test.
• Sample size and power — the calculation that determines whether the whole trial is even feasible. Learn how the required N moves with the effect size, the variance, and α/β.
• Effect sizes — a p-value tells you if the effect exists; the effect size tells you if it matters. Report both.

Layer 2 — trial methodology

The design vocabulary that makes a trial defensible:

• Randomisation — simple, stratified, block, minimisation. Why randomisation is what buys the causal claim.
• Blinding — single, double, triple. What each protects against.
• Design families — parallel-group, crossover, factorial, cluster-randomised, adaptive. Each has its own analysis and sample-size rules.
• Intention-to-treat (ITT) vs per-protocol — the choice that decides whom you actually analyse. ITT keeps the randomisation intact and is the regulatory default; per-protocol answers a different (and often narrower) question.
• Hypothesis framing — superiority (is A better than B?), non-inferiority (is A no worse than B by a specified margin?), equivalence (are A and B similar within a specified margin?). The choice drives the analysis and the sample size.
• Endpoint types — continuous, binary, time-to-event (survival analysis), ordinal, repeated. Each has a canonical analysis: t-test/ANCOVA, chi-square/logistic, Kaplan–Meier + log-rank + Cox, and MMRM for repeated.
• Missing data — MCAR / MAR / MNAR. Why last-observation-carried-forward is out of favour and multiple imputation is in.
• Estimands — ICH E9(R1) reframed the discipline around "what exactly are we estimating?" It's the modern lens for handling intercurrent events (treatment discontinuation, rescue therapy) that used to get quietly hand-waved.

Layer 3 — specialist methods and tools

Once the design vocabulary is fluent, the advanced work:

• Adaptive designs — response-adaptive randomisation, sample-size re-estimation, group-sequential designs with alpha spending. The trial modifies itself in flight while preserving type I error.
• Multiplicity — when a trial has multiple primary endpoints, subgroup analyses, or interim looks, controlling the family-wise error rate matters. Bonferroni, Holm, Hochberg, gate-keeping.
• MMRM (mixed model for repeated measures) — the standard analysis for longitudinal continuous endpoints (e.g. weekly symptom scores). Handles the missing-at-random case without imputation.
• Multiple imputation — the modern default for missing data; combines M imputed datasets and pools the estimates with Rubin's rules.
• Bayesian trials — increasingly used in early phase (dose-finding) and in trials where frequentist recruitment is impractical.

The tools working biostatisticians actually use:

• SAS — the historical regulatory standard; still the lingua franca of submission-grade output. Commercial.
• R (Clinical Trials task view) — the open-source pillar: survival, nlme/lme4 (mixed models), mice (multiple imputation), rpact and gsDesign (group-sequential), pwr (power).
• Stata — heavy in academic biostatistics and epi; excellent for survey-weighted analyses (svy).
• EAST / ADDPLAN / East Bayes — commercial specialist packages for adaptive- and group-sequential design.

Where thericerca can help — and where it can't

Trial biostatistics ranges from the everyday (a baseline table, a t-test on the primary endpoint) to the highly specialised (an adaptive Bayesian dose-finding design). thericerca handles the everyday layer honestly and doesn't pretend to do the specialised part.

Resources worth your time

• Books. Piantadosi, Clinical Trials: A Methodologic Perspective, is the clearest single introduction. Friedman, Furberg, DeMets, Fundamentals of Clinical Trials, is the classical reference every graduate program uses. For statistical methods specifically, Pocock's Clinical Trials: A Practical Approach and Machin & Campbell's Design of Studies for Medical Research are excellent.
• Regulatory guidance. ICH E9 (Statistical Principles for Clinical Trials) is the foundational document; ICH E9(R1) adds the modern estimands framework. Both are free, short, and worth reading once through.
• Reporting. The CONSORT statement is the checklist that every reputable journal expects for trial reports. Reading the checklist once will teach you what a well-reported trial looks like.
• Practice datasets. The ovarian, rats, and colon datasets in R's survival package are the standard teaching sets for time-to-event analysis. The lifelines library's Rossi dataset (used in our recidivism sample study) is another good one for Cox regression.
• Community. The R Consortium's R for Clinical Trials working group and PSI (Statisticians in the Pharmaceutical Industry) run excellent free webinars.

A concrete first month

If you're starting from a general stats background, spend the first week getting fluent in ANCOVA and why it's the default for continuous baseline-adjusted analyses. Week two, learn survival analysis end-to-end (Kaplan–Meier + log-rank + Cox). Week three, work through ICH E9 and the estimands addendum — it will reframe how you read every trial paper. Week four, do a mock analysis on a real dataset: baseline table, primary analysis, sensitivity analysis, and a short report.

thericerca can carry most of the applied work in that first month. Use the guided study pipeline for the ANCOVA, survival, and repeated-measures analyses; use sample size for the design questions; use reliability for any endpoint-measurement validation; use thetest-picker when you're not sure whether a paired or independent comparison is right; and hand the reviewer the reproducibility export so they can rerun everything themselves.

For the specialist layer — adaptive designs, MMRM, multiple imputation, regulatory submission formatting — you'll graduate to R, SAS, or EAST. That's the way in, and there's no shortcut. But the applied fluency you build first is what keeps you from being lost in the SAP template when you get there.